European Pharmaceutical Review

JULY 4, 2024

It begs the question of why only two botanical drug products have obtained FDA approval and fulfilled the Botanical Guidance definition of a botanical product. Prior to joining Fieldfisher, Taly spent four years working as in-house counsel for a leading tech company helping launch products across multiple EU markets.

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

pharmaphorum

OCTOBER 16, 2020

The repurposing of drugs is becoming more common, especially in the field of rare diseases. Now, as part of lifecycle management, pharmaceutical companies are looking more closely at drugs they have on their shelves. In the past, repurposing has mostly been driven by academics looking for new possibilities in generics.

Drug Development 105

Drug Development Immunization Immunity Pharmaceutical Companies 105

pharmaphorum

APRIL 28, 2022

For pharmaceutical companies, rare diseases present many challenges. The new hub will focus on centralising things like clinical development strategy, clinical operations, and regulatory approval strategy – not necessarily drug development itself. How big pharma tackles rare diseases.

Immunization 59

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies 59

Viseven

JANUARY 4, 2023

This article will cover the most important areas of AI influence on the pharma industry and new drugs development. What is Artificial Intelligence in Pharmaceutical Industry? Drug Development and Discovery. We analyzed the recent market research and are ready to share it with you.

Drug Development 52

Drug Development Medical Records Communication Pharmaceutical Companies 52

European Pharmaceutical Review

DECEMBER 21, 2022

All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. He is currently group leader of the Technology Development and Discovery Group at the Bioprocess Laboratory of the ETH. in South San Francisco, CA, USA.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

JANUARY 13, 2025

3 Encouragingly, there are many examples of the life sciences sector seeking to embrace sustainable drug development; reconciling the drive for innovation with the need to reduce waste and emissions produced during the R&D process, as well as throughout the product lifecycle.

Packaging 52

Packaging Community Pharmacies Documentation Pharmaceutical Companies 52

pharmaphorum

MARCH 30, 2021

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID.

Hospitals 111

Hospitals Communication Drug Development Pharmaceutical Companies 111